Literature DB >> 23285404

Podoplanin in the development and progression of oral cavity cancer: a preliminary study.

F N Bartuli1, F Luciani, F Caddeo, S Compagni, P Piva, L Ottria, C Arcuri.   

Abstract

OBJECTIVE.: Podoplanin is a mucin-like glycoprotein that is important in lymphangiogenesis but not in blood vessel formation. The aim of this preliminary study is to determine the role of podoplanin in the development and progression of head and neck cancer. MATERIAL AND METHODS.: Podoplanin over expression was analyzed in 20 patients with oral cancer, by immunohistochemical analysis. RESULT.: Podoplanin is not expressed in normal oral epithelial cells but was found in some hyperplastic and dysplastic lesions. Podoplanin high expression was found in 9 of 20 patients and was more frequent in cancers with lymph node metastasis, particularly in oral cavity cancers. In our preliminary study, patients who showed high levels of podoplanin had a statistically greater rate of lymph node metastasis (P<0,001); patients with lymph node metastasis and high-level podoplanin showed a shorter disease-specific survival (P = 0,004) than other patients. CONCLUSION.: The results of our preliminary study have provided interesting and encouraging data. We have observed that podoplanin expression increases in the early stages of tumourigenesis and it seems to be associated with a higher risk of head and neck cancer. While in squamous cell carcinoma podoplanin expression diminishes during tumour progression. These data support a role for podoplanin expression in the initiation but not in the progression of cancer. So we can conclude that podoplanin is involved in oral oncogenesis and can be a predictor for lymph node metastasis in asymptomatic patients. Histology and podoplanin analysis can be very useful to predict the risk of development, invasion and metastatic progression of a tumour in patients with oral cancer.

Entities:  

Keywords:  cancer diagnosis; monoclonal antibody; oral cancer; podoplanin

Year:  2012        PMID: 23285404      PMCID: PMC3505098     

Source DB:  PubMed          Journal:  Oral Implantol (Rome)        ISSN: 1974-5648


  12 in total

1.  Molecular markers of the risk of oral cancer.

Authors:  S M Lippman; W K Hong
Journal:  N Engl J Med       Date:  2001-04-26       Impact factor: 91.245

2.  A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors.

Authors:  Harriette J Kahn; Alexander Marks
Journal:  Lab Invest       Date:  2002-09       Impact factor: 5.662

Review 3.  Focus on head and neck cancer.

Authors:  Li Mao; Waun K Hong; Vassiliki A Papadimitrakopoulou
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

4.  Overexpression of podoplanin in oral cancer and its association with poor clinical outcome.

Authors:  Ping Yuan; Stephane Temam; Adel El-Naggar; Xian Zhou; Diane D Liu; J Jack Lee; Li Mao
Journal:  Cancer       Date:  2006-08-01       Impact factor: 6.860

5.  Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma.

Authors:  Yukinari Kato; Mika Kaneko; Makoto Sata; Naoya Fujita; Takashi Tsuruo; Motoki Osawa
Journal:  Tumour Biol       Date:  2005-07-07

6.  Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas.

Authors:  Ester Martín-Villar; Francisco G Scholl; Carlos Gamallo; Maria M Yurrita; Mario Muñoz-Guerra; Jesús Cruces; Miguel Quintanilla
Journal:  Int J Cancer       Date:  2005-03-01       Impact factor: 7.396

7.  Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431.

Authors:  Naho Atsumi; Genichiro Ishii; Motohiro Kojima; Masaru Sanada; Satoshi Fujii; Atsushi Ochiai
Journal:  Biochem Biophys Res Commun       Date:  2008-06-06       Impact factor: 3.575

Review 8.  The role of podoplanin in tumor progression and metastasis.

Authors:  Marius Raica; Anca Maria Cimpean; Domenico Ribatti
Journal:  Anticancer Res       Date:  2008 Sep-Oct       Impact factor: 2.480

9.  Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung.

Authors:  Yoshihisa Shimada; Genichiro Ishii; Kanji Nagai; Naho Atsumi; Satoshi Fujii; Atsushi Yamada; Yuki Yamane; Tomoyuki Hishida; Mitsuyo Nishimura; Junji Yoshida; Norihiko Ikeda; Atsushi Ochiai
Journal:  Cancer Sci       Date:  2009-07-21       Impact factor: 6.716

10.  Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation.

Authors:  Kimberly L Dumoff; Christina S Chu; Eleanor E Harris; David Holtz; Xiaowei Xu; Paul J Zhang; Geza Acs
Journal:  Mod Pathol       Date:  2006-05       Impact factor: 7.842

View more
  9 in total

1.  Low-risk population among patients with tumor-node-metastasis stage III/IV oral squamous cell carcinoma.

Authors:  Tohru Ikeda; Sachiko Seki; Mutsunori Fujiwara; Masaaki Matsuura; Yuu Ozaki-Honda; Shuichi Fujita; Hisazumi Ikeda; Masahiro Umeda; Izumi Asahina
Journal:  Oncol Lett       Date:  2017-07-15       Impact factor: 2.967

2.  Evaluation of the prognostic role of tumor cell podoplanin expression in locally advanced squamous cell carcinoma of the head and neck.

Authors:  Stefan Huttenlocher; Nina D Seibold; Maximilian P Gebhard; Frank Noack; Christoph Thorns; Katrin Hasselbacher; Barbara Wollenberg; Steven E Schild; Dirk Rades
Journal:  Strahlenther Onkol       Date:  2014-06-14       Impact factor: 3.621

3.  Prognostic Value of Podoplanin in Various Tumors.

Authors:  Xiaohang Wang; Xueying Wang; Vladmir Carvalho; Qianqian Wang; Tingting Li; Jinbang Wang; Yang Chen; Chengming Ni; Subo Liu; Jiaxin Zhang
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

4.  Prognostic value of podoplanin expression in oral squamous cell carcinoma--a regression model auxiliary to UICC classification.

Authors:  Sachiko Seki; Mutsunori Fujiwara; Masaaki Matsuura; Shuichi Fujita; Hisazumi Ikeda; Masahiro Umeda; Izumi Asahina; Tohru Ikeda
Journal:  Pathol Oncol Res       Date:  2013-11-28       Impact factor: 3.201

5.  Podoplanin, ezrin, and Rho-A proteins may have joint participation in tumor invasion of lip cancer.

Authors:  Agnes Assao; Suely Nonogaki; José Roberto Pereira Lauris; André Lopes Carvalho; Clóvis Antônio Lopes Pinto; Fernando Augusto Soares; Luiz Paulo Kowalski; Denise Tostes Oliveira
Journal:  Clin Oral Investig       Date:  2016-09-14       Impact factor: 3.573

6.  Are podoplanin and ezrin involved in the invasion process of the ameloblastomas?

Authors:  Y F Costa; K C Tjioe; S Nonogaki; F A Soares; J R Pereira Lauris; D Tostes Oliveira
Journal:  Eur J Histochem       Date:  2015-02-24       Impact factor: 3.188

7.  High expression of podoplanin in squamous cell carcinoma of the tongue occurs predominantly in patients ≤40 years but does not correlate with tumour spread.

Authors:  Nicola Sgaramella; Eva Lindell Jonsson; Linda Boldrup; Luigi Califano; Philip J Coates; Gianpaolo Tartaro; Lorenzo Lo Muzio; Robin Fåhraeus; Giuseppe Colella; Giovanni Dell'Aversana Orabona; Lotta Loljung; Mario Santagata; Riccardo Rossiello; Torben Wilms; Karin Danielsson; Göran Laurell; Karin Nylander
Journal:  J Pathol Clin Res       Date:  2015-10-09

8.  Moesin expression by tumor cells is an unfavorable prognostic biomarker for oral cancer.

Authors:  Francisco Bárbara Abreu Barros; Agnes Assao; Natália Galvão Garcia; Suely Nonogaki; André Lopes Carvalho; Fernando Augusto Soares; Luiz Paulo Kowalski; Denise Tostes Oliveira
Journal:  BMC Cancer       Date:  2018-01-08       Impact factor: 4.430

9.  Expression of Podoplanin in Different Grades of Oral Squamous Cell Carcinoma.

Authors:  B Prasad; B Kashyap; G S Babu; G R Kumar; R Manyam
Journal:  Ann Med Health Sci Res       Date:  2015 Jul-Aug
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.